Robin Mansukhani
Amministratore Delegato presso Deciduous Therapeutics, Inc.
Posizioni attive di Robin Mansukhani
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Deciduous Therapeutics, Inc.
 Deciduous Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Deciduous Therapeutics, Inc. engages in the biotechnology business. It develops novel therapies to activate the endogenous immune system to treat age related diseases. The company is headquartered in San Francisco, CA. | Direttore/Membro del Consiglio | - | - |
| Amministratore Delegato | - | - | |
| Presidente | - | - |
Storia della carriera di Robin Mansukhani
Precedenti posizioni note di Robin Mansukhani
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Alzeca Biosciences, Inc.
 Alzeca Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Alzeca Biosciences, Inc. is a company based in Houston, TX. Alzeca is developing a proprietary intravenous contrast agent that targets Alzheimer's disease pathology. The company's targeted agent has shown the ability to detect early stage disease pathology with exceptional resolution and sensitivity using commonly available imaging techniques. The development of the agent was initiated through a collaboration between Dr. Ananth Annapragada and Dr. Jason Eriksen. The company was founded in 2012 by Jason Eriksen, Robin Mansukhani, Ananth Annapragada. The CEO is Carlo Giovanni Medici. | Fondatore | - | 01/01/2012 |
Statistiche
Distribuzione geografica
| Stati Uniti | 3 |
Posizioni
| Founder | 1 |
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
Settori
| Commercial Services | 2 |
| Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
Alzeca Biosciences, Inc.
Alzeca Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Alzeca Biosciences, Inc. is a company based in Houston, TX. Alzeca is developing a proprietary intravenous contrast agent that targets Alzheimer's disease pathology. The company's targeted agent has shown the ability to detect early stage disease pathology with exceptional resolution and sensitivity using commonly available imaging techniques. The development of the agent was initiated through a collaboration between Dr. Ananth Annapragada and Dr. Jason Eriksen. The company was founded in 2012 by Jason Eriksen, Robin Mansukhani, Ananth Annapragada. The CEO is Carlo Giovanni Medici. | Commercial Services |
Deciduous Therapeutics, Inc.
Deciduous Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Deciduous Therapeutics, Inc. engages in the biotechnology business. It develops novel therapies to activate the endogenous immune system to treat age related diseases. The company is headquartered in San Francisco, CA. | Health Technology |
- Borsa valori
- Insiders
- Robin Mansukhani
- Esperienza
